Ageas Earnings Call Highlights Growth, Cash And M&A

Ageas Sa/Nv Sponsored ADR ((AGESY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Ageas Sa/Nv reported a broadly upbeat earnings call, with management highlighting robust growth, stronger capital and rising cash generation. Results were flattered by some one‑offs, notably a large tax benefit in China and a chunky reinsurance deal, but the tone remained confident as upgraded targets and recent acquisitions are expected to sustain momentum despite regional headwinds.

Strategic M&A and Market Positioning

Ageas doubled down on its strategic shift in the U.K., closing the Saga deal in July and esure in September, which together propel it into the top three in U.K. personal lines. The group also agreed to buy the remaining stake in Belgian subsidiary AG, with closing expected by Q2 2026, securing full ownership of its core home‑market profit engine.

Group Inflows Growth

The group delivered more than 9% inflow growth at constant currency, signaling healthy demand across its franchise. Non‑Life inflows jumped 16% with broad‑based gains across segments, while Europe Life PVNBP rose 17%, helped mainly by strong momentum in Türkiye despite macro challenges there.

Strong Net Operating Result

Net operating result came in above €1.655 billion, topping prior guidance and marking a sharp improvement in profitability. Non‑Life net operating profit climbed 21% to €548 million, while Life surged 39% year on year to €1.259 billion, though boosted by a non‑recurring tax gain in China.

Excellent Non‑Life Underwriting Performance

Underwriting discipline remained a clear highlight, with the group combined ratio at 92.5%, aided by unusually benign weather in Belgium. Third‑party reinsurance delivered an even stronger combined ratio of 76.5%, underscoring profitable growth in a business often seen as more volatile.

Healthy Cash Generation and Upstream Guidance

Ageas generated recurring cash upstreams of €949 million for 2025, an 18% rise and above its prior guidance range of €850–900 million. Management now expects cash upstreams to climb further to about €1.2 billion in 2026, supported by recent M&A and improving profitability.

Dividend and Shareholder Remuneration

The board proposed a total gross cash dividend of €3.75 per share, more than 7% higher than last year, with €1.50 already paid and €2.25 to follow in June. Longer term, the company raised its shareholder remuneration ambition to more than €2.2 billion over the current strategic cycle, signalling confidence in sustainable cash flows.

Capital Strength and Balance Sheet

Ageas emphasized its robust solvency and liquidity, with a Solvency II scope ratio around 211% and a non‑SII ratio at 244%, comfortably above regulatory requirements. Comprehensive equity increased to €17.5 billion, while cash at the holding stood at €1.45 billion, helped by a December RT1 capital issuance.

Operational Capital Generation

Operational capital generation reached €1.9 billion, reflecting solid underlying economics across the group’s insurance entities. Within this, Solvency II companies produced €1.2 billion, up 7% year on year, and operational free capital generation — the cash that can eventually be returned — amounted to €793 million.

Life Business Quality and New Business Metrics

Life insurance showed improved quality despite headline growth being partly driven by China’s tax one‑off, with the Life operating insurance service result up 4% year on year. Belgium Life net operating profit increased 5%, its guaranteed margin held at 102 basis points, and the group Life new business margin stood at a solid 7.9%, with Belgium’s margin up 110 bps to 6.8% and CSM adding €170 million.

Reinsurance Inflows and Growth

Reinsurance inflows reached €905 million, dominated by the Triglav/Prima deal which contributed €630 million and meaningfully boosted scale. Excluding that, reinsurance still grew well, with inflows up 29% to €275 million and 1 January 2026 renewals showing more than 20% growth on renewed business, indicating strong client demand.

One‑off China Tax Benefit

A key non‑recurring driver was a €300 million deferred tax benefit recognized in China linked to the IFRS 17/9 tax regime transition, which significantly lifted the Life net operating result. Management stressed that this gain will inflate 2025 comparatives and will not repeat, so investors should adjust expectations when assessing trend earnings.

Shift in China Product Mix and Margin Pressure

Ageas is reshaping its Chinese Life portfolio toward participating products that are more capital‑efficient but typically offer lower profitability per unit. With these products expected to represent roughly 70–80% of APE, the group acknowledged that new business and future Life margins could face structural pressure even as capital consumption improves.

Reliance on Non‑Recurring Reinsurance Deals

The large Prima reinsurance transaction played an outsized role in boosting reinsurance inflows and earnings this year, but its profit contribution was modest at about €7 million, with roughly €8 million expected next year. Management suggested this business may be phased out over the cycle, prompting questions on how sustainable current reinsurance volumes and margins will be.

Asia Tax Rate Uncertainty

Future earnings in Asia remain sensitive to tax treatment, particularly in Mainland China, where the effective tax rate is guided in a wide 0–10% range on the IFRS 17/9 base. The midpoint assumption of around 5% could shift depending on whether long‑term bond coupons are tax‑deductible, introducing ongoing volatility to reported profit.

Decreased Contribution from Non‑Solvency II Entities

Non‑Solvency II entities contributed €892 million, a decline versus the prior year that partly offset strength in core European operations. The general account actually consumed €187 million of capital, reflecting the current interest rate environment and a lower new business contribution from China, highlighting the importance of improving returns outside SII.

Increased Equity Exposure in Asia

After cutting risk in 2024, Ageas rebuilt equity exposure in its Asian portfolios during 2025 and also benefited from market gains, lifting absolute equity levels. While this supports investment returns, it slightly increases the group’s risk charge and makes solvency more sensitive to market swings, a trade‑off investors will watch closely.

U.K. Competitive and Claims Inflation Pressure

Despite the strategic scale‑up in the U.K., the operating backdrop remains tough as claims inflation stays high and market pricing has softened by 10–12%. Ageas applied only modest tariff hikes of about 2% in motor and property, which could squeeze margins if inflation persists, even as the esure and Saga deals drive top‑line expansion.

Country‑Specific Challenges

Türkiye’s Non‑Life business still faces severe inflation and motor line stress, limiting profitability even though it supports top‑line growth. The group also warned that exceptionally mild weather in Belgium, which supported Non‑Life results this year, is unlikely to repeat, potentially removing a temporary underwriting tailwind.

Margin Volatility and Timing Effects

Management cautioned that margins, especially in China, may show volatility due to the delayed impact of an automatic interest rate mechanism, meaning second‑half metrics may not reflect the underlying run‑rate. This timing effect introduces additional uncertainty into the 2026 results, making it harder to extrapolate near‑term margin trends.

Forward‑Looking Guidance and Outlook

Looking ahead, Ageas guided to a 2026 net operating result “well above” €1.5 billion, assuming a normal catastrophe burden and a group combined ratio below 93%, alongside cash upstreams of around €1.2 billion. Management reaffirmed its Elevate27 ambitions of free cash flow above €2.6 billion, shareholder payouts exceeding €2.2 billion and average EPS growth of 6–8%, supported by integration synergies at esure and full consolidation of AG.

Ageas’s earnings call painted the picture of a group in solid health, combining strong capital, rising cash generation and disciplined underwriting with ambitious but credible growth and payout targets. While one‑off benefits, mix shifts in China and regional pressures in the U.K. and Türkiye add complexity, management’s upgraded guidance and strategic M&A suggest a company leaning into growth while keeping a firm grip on risk.